National Bank of Canada
ALNY icon

National Bank of Canada’s Alnylam Pharmaceuticals ALNY Stock Holding History

National Bank of Canada’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Sell
52,467
-11,140
-18% -$3.36M 0.01% 616
2026
Q1 		$21M Sell
63,607
-2,826
-4% -$962K 0.02% 480
2025
Q4 		$26.4M Buy
66,433
+65,476
+6,842% +$29M 0.02% 451
2025
Q3 		$436K Buy
957
+54
+6% +$22K ﹤0.01% 1374
2025
Q2 		$294K Buy
903
+240
+36% +$66.4K ﹤0.01% 1534
2025
Q1 		$179K Sell
663
-5
-0.7% -$1.28K ﹤0.01% 1548
2024
Q4 		$157K Buy
668
+55
+9% +$14.5K ﹤0.01% 1662
2024
Q3 		$169K Sell
613
-13
-2% -$3.38K ﹤0.01% 1420
2024
Q2 		$152K Sell
626
-107,784
-99% -$17M ﹤0.01% 1389
2024
Q1 		$16.3M Buy
108,410
+107,897
+21,033% +$18M 0.02% 474
2023
Q4 		$100K Buy
513
+28
+6% +$4.77K ﹤0.01% 1574
2023
Q3 		$86.7K Sell
485
-2,781
-85% -$531K ﹤0.01% 1652
2023
Q2 		$620K Buy
3,266
+143
+5% +$28.4K ﹤0.01% 1254
2023
Q1 		$627K Sell
3,123
-1,109
-26% -$233K ﹤0.01% 1172
2022
Q4 		$1.01M Sell
4,232
-2,351
-36% -$501K ﹤0.01% 1083
2022
Q3 		$1.3M Sell
6,583
-5,617
-46% -$1.07M 0.01% 903
2022
Q2 		$1.81M Buy
12,200
+11
+0.1% +$1.56K 0.01% 815
2022
Q1 		$2.04M Buy
12,189
+7,382
+154% +$1.12M 0.01% 868
2021
Q4 		$796K Buy
+4,807
New +$893K ﹤0.01% 1126

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

National Bank of Canada's ALNY Position: Q2 2026 in Review

National Bank of Canada reduced its Alnylam Pharmaceuticals (ALNY) stake by 18% in Q2 2026, selling an estimated $3.36M and leaving 52,467 shares worth $15.8M. The position accounts for 0.01% of the portfolio, ranked #616.

National Bank of Canada first reported a position in ALNY in Q4 2021 and has held it in 19 quarters since. The position peaked at $26.4M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • National Bank of Canada held 52,467 shares of Alnylam Pharmaceuticals worth $15.8M as of Q2 2026.
  • National Bank of Canada sold 11,140 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3.36M.
  • Alnylam Pharmaceuticals made up 0.01% of National Bank of Canada's portfolio in Q2 2026, its #616 holding.
  • National Bank of Canada first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • National Bank of Canada's Alnylam Pharmaceuticals position peaked at $26.4M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.